Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology - PubMed (original) (raw)
Comparative Study
. 1996 Sep 1;56(17):3967-74.
A Hildesheim, M H Schiffman, J Lucci 3rd, D Contois, P Lawler, B B Rush, A T Lorincz, A Corrigan, R D Burk, W Qu, M A Marshall, D Mann, M Carrington, M Clerici, G M Shearer, D P Carbone, D R Scott, R A Houghten, J A Berzofsky
Affiliations
- PMID: 8752165
Comparative Study
Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology
T Tsukui et al. Cancer Res. 1996.
Abstract
Human papillomavirus (HPV) is believed to be the major cause of cervical cancer. To investigate whether a cellular immune response, especially a T helper type 1 response, is related to the natural defense against HPV-related cervical lesions, the interleukin 2 response of peripheral blood lymphocytes in vitro to overlapping peptides from HPV-16 E6 and E7 oncoproteins was compared with the degree of cervical cytological abnormality among 140 women in a cross-sectional study. We compared 66 women diagnosed with low-grade squamous intraepithelial lesions (LSIL), 21 with high-grade squamous intraepithelial lesions (HSIL), and 28 with invasive cervical cancer with 25 women who were cytologically normal but previously HPV-16 DNA positive. The fraction showing strong interleukin 2 production against HPV-16 peptides was greatest among cytologically normal women (35%) and declined with increasing disease severity [LSIL] (20%), HSIL, (17%), and cancer patients (7%); X2 test P for the trend = 0.02], whereas the responses against a recall influenza antigen were not significantly different among groups. Our finding suggests that a T helper lymphocyte type 1 response to HPV antigens is associated with disease status. This result may reflect a targeted effect of the disease on immune function or a protective effect of the immune response against disease progression.
Similar articles
- Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.
Hildesheim A, Schiffman MH, Tsukui T, Swanson CA, Lucci J 3rd, Scott DR, Glass AG, Rush BB, Lorincz AT, Corrigan A, Burk RD, Helgesen K, Houghten RA, Sherman ME, Kurman RJ, Berzofsky JA, Kramer TR. Hildesheim A, et al. Cancer Epidemiol Biomarkers Prev. 1997 Oct;6(10):807-13. Cancer Epidemiol Biomarkers Prev. 1997. PMID: 9332763 - Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia.
Bontkes HJ, de Gruijl TD, van den Muysenberg AJ, Verheijen RH, Stukart MJ, Meijer CJ, Scheper RJ, Stacey SN, Duggan-Keen MF, Stern PL, Man S, Borysiewicz LK, Walboomers JM. Bontkes HJ, et al. Int J Cancer. 2000 Oct 1;88(1):92-8. Int J Cancer. 2000. PMID: 10962445 - Proliferative T-cell responses to human papillomavirus type 16 E5 are decreased amongst women with high-grade neoplasia.
Gill DK, Bible JM, Biswas C, Kell B, Best JM, Punchard NA, Cason J. Gill DK, et al. J Gen Virol. 1998 Aug;79 ( Pt 8):1971-6. doi: 10.1099/0022-1317-79-8-1971. J Gen Virol. 1998. PMID: 9714245 - The roles of the human major histocompatibility complex and human papillomavirus infection in cervical intraepithelial neoplasia and cervical cancer.
Odunsi KO, Ganesan TS. Odunsi KO, et al. Clin Oncol (R Coll Radiol). 1997;9(1):4-13. doi: 10.1016/s0936-6555(97)80051-9. Clin Oncol (R Coll Radiol). 1997. PMID: 9039807 Review. No abstract available. - Immune response and immunotherapy in intraepithelial and invasive lesions of the uterine cervix.
Machado FA, Janssens JP, Michelin MA, Murta EF. Machado FA, et al. Clin Exp Obstet Gynecol. 2012;39(1):27-31. Clin Exp Obstet Gynecol. 2012. PMID: 22675951 Review.
Cited by
- Tumor immunity: A brief overview of tumor‑infiltrating immune cells and research advances into tumor‑infiltrating lymphocytes in gynecological malignancies (Review).
Wang ZT, Deng ZM, Dai FF, Yuan MQ, Liu SY, Li BS, Cheng YX. Wang ZT, et al. Exp Ther Med. 2024 Feb 26;27(4):166. doi: 10.3892/etm.2024.12453. eCollection 2024 Apr. Exp Ther Med. 2024. PMID: 38476909 Free PMC article. Review. - Vaginal delivery of vaccines.
VanBenschoten HM, Woodrow KA. VanBenschoten HM, et al. Adv Drug Deliv Rev. 2021 Nov;178:113956. doi: 10.1016/j.addr.2021.113956. Epub 2021 Sep 1. Adv Drug Deliv Rev. 2021. PMID: 34481031 Free PMC article. Review. - Gut Helminth Infection-Induced Immunotolerance and Consequences for Human Papillomavirus Persistence.
Clark EH, Gilman RH, Chiao EY, Gravitt PE. Clark EH, et al. Am J Trop Med Hyg. 2021 Jul 19;105(3):573-583. doi: 10.4269/ajtmh.21-0191. Am J Trop Med Hyg. 2021. PMID: 34280146 Free PMC article. Review. - Senescence-Associated Secretory Phenotype Determines Survival and Therapeutic Response in Cervical Cancer.
Purohit S, Zhi W, Ferris DG, Alverez M, Tran LKH, Tran PMH, Dun B, Hopkins D, Santos BD, Ghamande S, She JX. Purohit S, et al. Cancers (Basel). 2020 Oct 9;12(10):2899. doi: 10.3390/cancers12102899. Cancers (Basel). 2020. PMID: 33050319 Free PMC article. - Viral Modulation of TLRs and Cytokines and the Related Immunotherapies for HPV-Associated Cancers.
Barros MR Jr, de Oliveira THA, de Melo CML, Venuti A, de Freitas AC. Barros MR Jr, et al. J Immunol Res. 2018 May 2;2018:2912671. doi: 10.1155/2018/2912671. eCollection 2018. J Immunol Res. 2018. PMID: 29854832 Free PMC article. Review.